Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
Iran Attack in Strait of Hormuz Pushes Oil Prices Higher 
U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand 
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Tabletop particle accelerator could transform medicine and materials science 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Oil Prices Drop as Strait of Hormuz Shipping Recovers 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Asian Stocks Sink as Apple Price Hikes Spark AI Valuation Fears, South Korea and Japan Lead Selloff 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
BOJ Hawk Signals Faster Interest Rate Hikes Amid Inflation Risks 
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
